Merck reported positive results from two large trials of Welireg in renal cell carcinoma, outcomes that could expand use of the oral kinase inhibitor across kidney cancer populations. The data strengthen an oncology growth pillar for the company as Keytruda faces future patent pressure. The trials evaluated efficacy endpoints across sizable cohorts; topline success positions Welireg for broader clinical adoption and potential regulatory filings in additional kidney‑cancer settings. Merck framed the results as part of a late‑stage push to diversify its oncology portfolio beyond immunotherapy dominance. Physicians and payers will scrutinize comparative benefit, safety, and cost given multiple competing regimens in kidney cancer. The wins also matter for Merck’s commercial planning as it navigates Keytruda lifecycle transitions.